The United States District Court for the Southern District of New York has made a notable ruling on a securities class action case involving a biopharmaceutical company. On September 25, 2023, Judge Lorna Schofield granted a motion to dismiss a proposed class action against the firm — referred to as the “Company” — that was accused of violating Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The case was officially known as Gru v. Axsome Therapeutics, Inc., No. 22 CIV. 3925 (LGS), 2023 WL 6214581 (S.D.N.Y. Sept. 25, 2023).
The plaintiff in the case had alleged that the company failed to disclose pertinent details about its migraine drug. The undisclosed information, he claimed, played a significant role in the premise of his securities class action complaint.
However, granting the Company’s motion to dismiss, Judge Schofield stated that the plaintiff had not adequately established the loss causation, a vital component needed to maintain his claim. Loss causation — often a crucial point of contention in securities class actions — refers to the requirement for plaintiffs to demonstrate a causal connection between the defendants’ alleged misrepresentation and the economic harm suffered.
The Southern District of New York’s ruling serves as an important reminder for legal professionals about the stringent requirements for claims made under the Securities Exchange Act of 1934. It underscores the necessity for plaintiffs to thoroughly establish loss causation when bringing forth securities class actions.